You do know there are other BP and VAXINIA has already seen efficacy very early in Ph1 clinical trial usually seen close to end of Ph2 clinical trial which I agree with you is when BP tend to make T/O and then use their resource and fund to complete Ph3 clinical trial as quickly as possible.
Fast Track designation and path to registrational clinical trial are the catalyst for BP doing a T/O for IMU when Ph2 clinical trial start end of this year instead of waiting for completion of Ph2 clinical trial as it will allow them to essentially commence Ph2/Ph3 clinical trial so they don't need to do Ph2 and then Ph3, big difference.
IMU Price at posting:
3.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)